Galecto Inc. (GLTO): Price and Financial Metrics
GET POWR RATINGS... FREE!
GLTO Stock Price Chart Interactive Chart >
GLTO Price/Volume Stats
| Current price | $1.32 | 52-week high | $16.41 |
| Prev. close | $1.30 | 52-week low | $1.17 |
| Day low | $1.29 | Volume | 53,300 |
| Day high | $1.33 | Avg. volume | 72,858 |
| 50-day MA | $1.93 | Dividend yield | N/A |
| 200-day MA | $2.77 | Market Cap | 33.35M |
Galecto Inc. (GLTO) Company Bio
Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.
Latest GLTO News From Around the Web
Below are the latest news stories about Galecto Inc that investors may wish to consider to help them evaluate GLTO as an investment opportunity.
Galecto Reports Financial Results for the Year Ended December 31, 2021Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024 BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year ended December 31, 2021. “During 2021, we made significant progress with our pipeline as we advanced two additional |
Galecto to Participate at Upcoming Investor ConferencesBOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating virtually at two upcoming conferences. Details for both events are below: SVB Leerink Healthcare ConferenceDate:February 16, 2022Time:8:00 am ETWebcast:Register Here Credit Suisse London Healthcare ConferenceDate:March 1-4, 2022Format:Management will be available |
Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of CareResults Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease Company Provides Update on GALACTIC-1 Trial BOSTON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the publication of the full results of an investigator-initiated open and randomized trial to evaluate Galecto’s inhale |
Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Marquette Asset Management, LLC Buys Vanguard Total Bond Market ETF, ARK Next Generation ...Investment company Marquette Asset Management, LLC (Current Portfolio) buys Vanguard Total Bond Market ETF, ARK Next Generation Internet ETF, TAT Technologies, Avantis International Equity ETF, Dril-Quip Inc, sells Vanguard Short-Term Corporate Bond ETF, Vanguard Total Stock Market ETF, Vanguard FTSE Developed Markets ETF, Concord Acquisition Corp, Astrotech Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Marquette Asset Management, LLC. |
GLTO Price Returns
| 1-mo | -20.96% |
| 3-mo | -31.61% |
| 6-mo | -53.52% |
| 1-year | -75.14% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -56.44% |
| 2021 | -75.78% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...